GlassScriptPhysician profile
Mark G Berry
NPI 1336121938
$4,285.81
in general payments reported to CMS, 2019-2025
10 companies · $2,794 in 2025
The $2,794 reported for 2025 was more than what 87% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.69 · 2020: $17.73 · 2021: $453 · 2022: $311 · 2023: $63.06 · 2024: $629 · 2025: $2,794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,313 · Food and Beverage: $1,173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,313.15 |
| Food and Beverage | $1,173.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,493.50 | 2021-2025 | Aveir, Cardiomems, Accent |
| Zoll Respicardia, INC. | $347.80 | 2021 | |
| Boston Scientific Corporation | $129.84 | 2022-2025 | Watchman Flx |
| Itamar Medical INC | $93.14 | 2022 | |
| Medtronic, INC. | $68.69 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $52.19 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.57 | 2022 | |
| Shockwave Medical, INC | $33.10 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $14.95 | 2023 | Camzyos |
| Novartis Pharmaceuticals Corporation | $12.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Berry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.